{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T21:07:24Z","timestamp":1774818444485,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1124\/jpet.122.001289","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T10:20:24Z","timestamp":1659608424000},"page":"25-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Sodium-Glucose Cotransporter-2 Inhibition Exacerbates Hepatic Encephalopathy in Biliary Cirrhotic Rats"],"prefix":"10.1016","volume":"383","author":[{"given":"Shao-Jung","family":"Hsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Chun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chon Kit","family":"Pun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Chih","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiao-Lin","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Hsiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chih","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fa-Yauh","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.122.001289_bib1","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s12272-020-01237-y","article-title":"Empagliflozin alleviates neuronal apoptosis induced by cerebral ischemia\/reperfusion injury through HIF-1\u03b1\/VEGF signaling pathway","volume":"43","author":"Abdel-Latif","year":"2020","journal-title":"Arch Pharm Res"},{"key":"10.1124\/jpet.122.001289_bib2","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/0016-5085(92)90179-3","article-title":"Vasodilatation and sodium retention in prehepatic portal hypertension","volume":"102","author":"Albillos","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.122.001289_bib3","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3758\/s13420-020-00436-3","article-title":"Time-of-day affects the amount rats run during daily sessions in activity wheels","volume":"49","author":"Boakes","year":"2021","journal-title":"Learn Behav"},{"key":"10.1124\/jpet.122.001289_bib4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/path.1700750212","article-title":"Disturbances of structure and function in the liver as the result of biliary obstruction","volume":"75","author":"Cameron","year":"1958","journal-title":"J Pathol Bacteriol"},{"key":"10.1124\/jpet.122.001289_bib5","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3390\/ijms20071566","article-title":"Effects of caffeine treatment on hepatopulmonary syndrome in biliary cirrhotic rats","volume":"20","author":"Chang","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.122.001289_bib6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejphar.2017.02.039","article-title":"Effects of raloxifene on portal hypertension and hepatic encephalopathy in cirrhotic rats","volume":"802","author":"Chang","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.122.001289_bib7","first-page":"G371","article-title":"Measurement of portal-systemic shunting in the rat by using \u03b3-labeled microspheres","volume":"240","author":"Chojkier","year":"1981","journal-title":"Am J Physiol"},{"key":"10.1124\/jpet.122.001289_bib8","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1053\/j.gastro.2003.12.012","article-title":"Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice","volume":"126","author":"Fernandez","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.122.001289_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","article-title":"Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology","volume":"26","author":"Ferrannini","year":"2017","journal-title":"Cell Metab"},{"issue":"Suppl 2","key":"10.1124\/jpet.122.001289_bib10","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.2337\/dcS15-3006","article-title":"SGLT2 Inhibitors and the Diabetic Kidney","volume":"39","author":"Fioretto","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.122.001289_bib11","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1001\/archsurg.1979.01370330086016","article-title":"Portal hypertension after bile duct obstruction: effect of bile diversion on portal pressure in the rat","volume":"114","author":"Franco","year":"1979","journal-title":"Arch Surg"},{"key":"10.1124\/jpet.122.001289_bib12","doi-asserted-by":"crossref","first-page":"L1027","DOI":"10.1152\/ajplung.00167.2015","article-title":"SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery","volume":"309","author":"Han","year":"2015","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1124\/jpet.122.001289_bib13","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/pharmaceutics12040320","article-title":"Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats","volume":"12","author":"Hsu","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1124\/jpet.122.001289_bib14","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/JCMA.0000000000000636","article-title":"Effects of dipeptidyl peptidase-4 inhibition on portal hypertensive and cirrhotic rats","volume":"84","author":"Huang","year":"2021","journal-title":"J Chin Med Assoc"},{"key":"10.1124\/jpet.122.001289_bib15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13098-016-0169-x","article-title":"Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes","volume":"8","author":"Jojima","year":"2016","journal-title":"Diabetol Metab Syndr"},{"key":"10.1124\/jpet.122.001289_bib16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejphar.2018.03.043","article-title":"Canagliflozin protects against non-alcoholic steatohepatitis in type-2 diabetic rats through zinc alpha-2 glycoprotein up-regulation","volume":"828","author":"Kabil","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.122.001289_bib17","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.122.001289_bib18","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12933-018-0708-x","article-title":"SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice","volume":"17","author":"Lee","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1124\/jpet.122.001289_bib19","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1093\/eurheartj\/ehw110","article-title":"Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus","volume":"37","author":"Marx","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1124\/jpet.122.001289_bib20","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.3390\/ijms23073668","article-title":"SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease","volume":"23","author":"Mirarchi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.122.001289_bib21","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.3390\/molecules26237213","article-title":"Neuroprotective Effect of SGLT2 Inhibitors","volume":"26","author":"Pawlos","year":"2021","journal-title":"Molecules"},{"key":"10.1124\/jpet.122.001289_bib22","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ijcard.2017.03.089","article-title":"Mechanisms linking empagliflozin to cardiovascular and renal protection","volume":"241","author":"Perrone-Filardi","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1124\/jpet.122.001289_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106062","article-title":"Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment","volume":"176","author":"Rizzo","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1124\/jpet.122.001289_bib24","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1038\/s41598-018-19658-7","article-title":"Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH","volume":"8","author":"Shiba","year":"2018","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.122.001289_bib25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/jpet.122.001289_bib26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12933-017-0621-8","article-title":"Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study","volume":"16","author":"Solini","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1124\/jpet.122.001289_bib27","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1056\/NEJMra1600561","article-title":"Hepatic Encephalopathy","volume":"375","author":"Wijdicks","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001289_bib28","doi-asserted-by":"crossref","first-page":"H1662","DOI":"10.1152\/ajpheart.01242.2004","article-title":"Circadian periodicity of cerebral blood flow revealed by laser-Doppler flowmetry in awake rats: relation to blood pressure and activity","volume":"289","author":"Wauschkuhn","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1124\/jpet.122.001289_bib29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1124\/jpet.122.001289_bib30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40261-013-0089-6","article-title":"The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor","volume":"33","author":"Zhang","year":"2013","journal-title":"Clin Drug Investig"},{"key":"10.1124\/jpet.122.001289_bib31","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524003331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524003331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.122.001289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:26:47Z","timestamp":1739971607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524003331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0022356524003331"],"URL":"https:\/\/doi.org\/10.1124\/jpet.122.001289","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-Glucose Cotransporter-2 Inhibition Exacerbates Hepatic Encephalopathy in Biliary Cirrhotic Rats","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.122.001289","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}